medicationControlledSchedule IV (US)Prescription only (US)FDA-approved under brand names including Ambien, Ambien CR, Edluar, and Zolpimist for short-term treatment of insomniaFDA has issued boxed-warning-level safety communications about complex sleep behaviors, including sleepwalking and sleep-driving, associated with zolpidem
ZolpidemBenefits, Dosage & Interactions
Also known as: Ambien
Zolpidem is a prescription medication primarily used for the short-term treatment of insomnia. It belongs to a class of drugs known as sedative-hypnotics. It is typically taken in the evening. The reported plasma half-life is about 2.5 hours, which shapes dosing frequency.
How much Zolpidem do people take?
Meta-analysis-pooled trials and the lemborexant comparison used standard immediate-release and extended-release zolpidem doses studied for insomnia disorder, most commonly 5-10 mg (immediate release) or 6.25-12.5 mg (extended release) at bedtime. Route reported: Oral tablet, taken immediately before bedtime. Frequency reported: Once nightly, as needed for sleep onset or maintenance difficulty. These are amounts documented in the cited studies and labels for Zolpidem — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
See the full reported protocol and its sourcesResearched by DoseRoutine Research TeamReviewed for accuracy by Nicholas Alexander, RSE, SO, PMPLast updated Educational reference only — not medical advice. Always confirm dosing and safety decisions with a licensed clinician.
Evidence: Strong — 2 human randomized trials and regulatory approval on file.
Evidence strengthStrong · 4/4
PreclinicalStrong human evidence
2 human randomized trials and regulatory approval on file.
Plasma half-life
~2.5 h
Typical timing
in the evening
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- Meta-analysis-pooled trials and the lemborexant comparison used standard immediate-release and extended-release zolpidem doses studied for insomnia disorder, most commonly 5-10 mg (immediate release) or 6.25-12.5 mg (extended release) at bedtime[1][2][3]
- Cycle length
- Trials in the pooled meta-analysis and the phase 3 lemborexant comparison ran for one month[1][2][3]
Reported for Zolpidem in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Zolpidem entry is written from. Each number matches an inline marker above.
- [1]Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical TrialRosenberg R, Murphy P, Zammit G, Mayleben D, Kumar D, Dhadda S, Filippov G, LoPresti A, Moline M · JAMA Network Open · 2019 · Peer-reviewed · PMID 31880796
- [2]Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysisDe Crescenzo F, D'Alò GL, Ostinelli EG, Ciabattini M, Di Franco V, Watanabe N, Kurtulmus A, Tomlinson A, Mitrova Z, Foti F, Del Giovane C, Quested DJ, Cowen PJ, Barbui C, Amato L, Efthimiou O, Cipriani A · The Lancet · 2022 · Peer-reviewed · PMID 35843245
- [3]Efficacy and safety of Zolpidem in the treatment of insomnia disorder for one month: a meta-analysis of a randomized controlled trialXiang T, Cai Y, Hong Z, Pan J · Sleep Medicine · 2021 · Peer-reviewed · PMID 34688027
References & Evidence
Sources on this page that document Zolpidem dosing, timing and safety.
- [1]U.S. National Library of Medicine View source
- [2]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Zolpidem?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Zolpidem is a prescription medication primarily used for the short-term treatment of insomnia. It belongs to a class of drugs known as sedative-hypnotics. The medication is designed to help individuals fall asleep more quickly. Zolpidem is available in various formulations, including immediate-release tablets, extended-release tablets, sublingual tablets, and an oral spray. It is commonly known by its brand name, Ambien, among others. Due to its potential for dependence and adverse effects, Zolpidem is generally recommended for short-term use, typically for one to two weeks, as advised by a healthcare professional (NIH MedlinePlus). Its use is restricted to individuals who have difficulty initiating sleep.
What does the research say about Zolpidem?
Tap a section to expand.
Zolpidem exerts its hypnotic and sedative effects by selectively binding to specific gamma-aminobutyric acid (GABA) A receptor subtypes in the brain. GABA is the primary inhibitory neurotransmitter in the central nervous system. By enhancing the effects of GABA at these specific receptor sites (alpha-1 subunit containing GABA-A receptors), zolpidem promotes neuronal inhibition, leading to decreased brain activity. This reduction in activity helps to induce sleep. Unlike some older sedative-hypnotics, zolpidem is considered more selective in its action, which may contribute to a different side effect profile. Its binding is distinct from benzodiazepines, although both enhance GABAergic transmission. This selective binding allows zolpidem to primarily affect sleep induction and maintenance without causing significant anxiolytic or muscle relaxant effects at typical doses (DrugBank, FDA label).
Source for this section: Sources for How does Zolpidem work?: Jumps to this entry in the sources and references list at the end of the page.
The primary benefit of zolpidem is its effectiveness in facilitating sleep onset for individuals suffering from insomnia. Clinical studies, as detailed in various FDA labels and reviewed by sources like DrugBank, have demonstrated that zolpidem helps shorten the time it takes to fall asleep. Some formulations, particularly extended-release versions, are also designed to help maintain sleep throughout the night. For individuals experiencing transient or chronic insomnia, zolpidem can temporarily improve sleep quality and quantity. However, it's crucial to note that zolpidem addresses the symptom of sleeplessness rather than the underlying causes of insomnia, which may require additional therapeutic approaches (Mayo Clinic, FDA label).
Numerous clinical trials have supported the efficacy of zolpidem for the short-term treatment of insomnia. A review of studies published by the National Institutes of Health (NIH) and detailed in FDA prescribing information consistently shows that zolpidem significantly reduces sleep latency (the time it takes to fall asleep) compared to placebo. For instance, studies on immediate-release zolpidem tablets typically show a statistically significant reduction in sleep onset time within 7 to 14 nights of treatment. Extended-release formulations have also demonstrated efficacy in improving sleep maintenance, often measured by increased total sleep time and reduced wakefulness after sleep onset (FDA label). While effective for short-term use, evidence regarding the long-term efficacy and safety of zolpidem beyond a few weeks is less robust, leading to recommendations for its brief use. Comparisons against other hypnotics and placebo are frequently conducted to establish its therapeutic profile (Cochrane Library reviews often include such comparisons).
Common side effects associated with zolpidem use include dizziness, drowsiness, headache, nausea, and diarrhea. Some individuals may experience memory problems, particularly anterograde amnesia, where they have no recollection of events that occurred after taking the medication. More serious, but less common, side effects can include complex sleep behaviors such as sleep-driving, sleep-walking, or preparing and eating food while not fully awake, with no memory of the event afterward. Other potential adverse effects include allergic reactions, behavioral changes like aggression or hallucinations, and worsening depression. Patients may also experience residual daytime drowsiness or impaired coordination. The risk of these side effects can be increased with higher doses or concomitant use of other central nervous system depressants (FDA label, NIH MedlinePlus). This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Source for this section: Sources for What are the side effects of Zolpidem?: Jumps to this entry in the sources and references list at the end of the page.
Zolpidem carries several significant warnings. It is a Schedule IV controlled substance due to its potential for abuse and dependence. Prolonged use can lead to physical and psychological dependence, and withdrawal symptoms can occur upon abrupt discontinuation, including rebound insomnia, nausea, sweating, and tremors. Complex sleep behaviors, such as sleep-driving, making phone calls, or preparing and eating food while not fully awake and having no memory of the event, are a serious risk. Patients should be warned about these potential events. Zolpidem can also impair driving ability and the ability to perform other hazardous tasks the day after administration, especially with extended-release forms or higher doses. Concomitant use with other CNS depressants, including alcohol, significantly increases the risk of respiratory depression and profound sedation. Caution is advised in patients with underlying respiratory disease or impaired hepatic function (FDA label, Mayo Clinic). This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Source for this section: Sources for Who should avoid Zolpidem?: Jumps to this entry in the sources and references list at the end of the page.
Zolpidem is contraindicated in patients with known hypersensitivity to zolpidem or any of its inactive ingredients. It should not be used in individuals who have experienced complex sleep behaviors after taking zolpidem previously. Severe hepatic impairment is a contraindication as it can significantly reduce the clearance of zolpidem, leading to higher drug levels and increased risk of adverse effects. Patients with severe respiratory insufficiency or acute pulmonary insufficiency may also have contraindications due to the risk of respiratory depression. Zolpidem is generally not recommended for use in children or adolescents (FDA label). This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Source for this section: Sources for When should Zolpidem not be taken?: Jumps to this entry in the sources and references list at the end of the page.
Zolpidem should not be mixed with alcohol, as this combination can significantly enhance the depressive effects on the central nervous system, leading to severe sedation, respiratory depression, coma, and even death. It should also be used with caution, or generally avoided, when taken with other central nervous system depressants such as benzodiazepines (e.g., lorazepam, alprazolam), opioids (e.g., oxycodone, hydrocodone), certain antidepressants that cause sedation, muscle relaxants, and other sedative-hypnotics. These combinations can increase the risk of over-sedation, respiratory depression, and impaired psychomotor performance. Additionally, certain medications that inhibit cytochrome P450 3A4 (CYP3A4) enzymes (e.g., ketoconazole, clarithromycin, ritonavir) can increase zolpidem levels and effects, while CYP3A4 inducers (e.g., rifampin, St. John's Wort) can decrease its effectiveness. Consult the official prescribing information for a comprehensive list of interactions (FDA label). This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Source for this section: Sources for What should you not mix with Zolpidem?: Jumps to this entry in the sources and references list at the end of the page.
Zolpidem is typically taken immediately before going to bed, or after a patient has gone to bed and has difficulty falling asleep. It should only be taken when the individual has a full 7 to 8 hours to sleep before needing to be active again. Due to its rapid onset of action, it is important not to take zolpidem unless immediate sleep is intended. Taking zolpidem with or immediately after a high-fat meal can delay its absorption and overall effect, making it less effective for rapid sleep onset; therefore, it is often recommended to take it on an empty stomach for optimal results. The dose is user-directed and must be set by a licensed clinician. It is never to be taken more than once per night (FDA label).
Source for this section: Sources for When should you take Zolpidem?: Jumps to this entry in the sources and references list at the end of the page.
Put it into practice
Reading about Zolpidem is the first step — DoseRoutine helps you act on it. These free tools turn what you just learned into a routine.
What interacts with Zolpidem?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any supplement + medication | Note | Category ruleConfidence: theoretical | Some supplements change how the body processes medications (absorption, liver enzymes, or additive effects).Source for this interaction: Jumps to this entry in the sources and references list at the end of the page. | Specific pairs are checked against a licensed drug database and shown with their own severity. Always confirm with your provider or pharmacist. |
| Any vitamin + medication | Note | Category ruleConfidence: theoretical | Certain vitamins interact with specific medications (e.g., vitamin K with blood thinners).Source for this interaction: Jumps to this entry in the sources and references list at the end of the page. | Specific pairs are checked against a licensed source; confirm with your provider. |
| Melatonin | Note | Compound pairConfidence: theoretical | Additive sedation possible.Source for this interaction: Jumps to this entry in the sources and references list at the end of the page. | Start at low melatonin dose (0.3–1 mg) when combined with prescription sedatives. |
| Ashwagandha | Note | Compound pairConfidence: theoretical | Additive sedation possible.Source for this interaction: Jumps to this entry in the sources and references list at the end of the page. | Use lower doses when combined. |
Frequently asked questions about Zolpidem
Zolpidem typically starts to work very quickly, usually within 15 to 30 minutes after taking it. This rapid onset is why it's advised to take it right before bedtime when you are ready to sleep and have a full night available for rest (FDA label).
Zolpidem is generally recommended for short-term treatment of insomnia, typically for one to two weeks. Its long-term use is not usually advised due to the potential for dependence, tolerance, and adverse effects such as complex sleep behaviors. For chronic insomnia, a healthcare provider may suggest alternative treatments (Mayo Clinic).
Complex sleep behaviors are serious side effects where individuals engage in activities like sleep-driving, sleep-walking, or preparing and eating food while not fully awake, with no memory of these events. These behaviors can be dangerous and warrant immediate discontinuation of the medication and consultation with a doctor (FDA label).
Zolpidem can impair driving ability and the ability to perform other tasks requiring alertness the morning after use, especially with extended-release forms or higher doses. It's crucial to ensure you are fully awake and free of any residual drowsiness before driving or operating machinery. If you experience lingering effects, avoid such activities (NIH MedlinePlus).
If you forget to take your dose of zolpidem and it's already late in the night, or you don't have at least 7 to 8 hours remaining for sleep, it's best to skip the missed dose and not take it. Never take a double dose to make up for a missed one, as this increases the risk of side effects (FDA label).
As a medication, Zolpidem can overlap with other supplements, prescription medicines, hormones and peptides. Because Zolpidem is usually taken in the evening, most avoidable conflicts come from what else lands in that same window. With a reported plasma half-life near 2.5 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Zolpidem with no sign-up.
Whether Zolpidem fits alongside testosterone replacement therapy depends on the protocol — dose, ester and ancillaries such as HCG or anastrozole — and on current bloodwork. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
"Peptides" is not one category — healing peptides, GLP-1 agonists, growth-hormone secretagogues and melanocortins each behave differently next to Zolpidem. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
A short plasma half-life of roughly 2.5 hours is why protocols often split Zolpidem across the day rather than using a single dose. It is typically taken in the evening. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
Because Zolpidem clears quickly (plasma half-life around 2.5 hours), a missed dose leaves a real gap in exposure rather than being buffered by what is still in your system. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For Zolpidem the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Meta-analysis-pooled trials and the lemborexant comparison used standard immediate-release and extended-release zolpidem doses studied for insomnia disorder, most commonly 5-10 mg (immediate release) or 6.25-12.5 mg (extended release) at bedtime. Route reported: Oral tablet, taken immediately before bedtime. Frequency reported: Once nightly, as needed for sleep onset or maintenance difficulty. These are amounts documented in the cited studies and labels for Zolpidem — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
Which studies looked at Zolpidem?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial(opens PubMed in a new tab)JAMA Netw Open · 2019 · PMID 31880796 · https://pubmed.ncbi.nlm.nih.gov/31880796/
- 2.Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications.(opens PubMed in a new tab)Clinical pharmacokinetics · 1995 · PMID 8521677 · https://pubmed.ncbi.nlm.nih.gov/8521677/
- 3.Zolpidem for the Management of Catatonia: A Systematic Review(opens PubMed in a new tab)J Acad Consult Liaison Psychiatry · 2025 · PMID 39522949 · https://pubmed.ncbi.nlm.nih.gov/39522949/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- MedlinePlus(opens in a new tab)U.S. National Library of Medicine · medlineplus.gov/druginfo/meds/a693025.html
- PubChem CID 441338(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/441338
Verify at
Publisher search links for Zolpidem. These are places to check the information — they are not citations, so they are not numbered.
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- FDA-approved labeling (DailyMed)(publisher search, opens in a new tab)U.S. Food and Drug Administration · publisher search
- Mayo Clinic(publisher search, opens in a new tab)Mayo Clinic · publisher search
- Cochrane Library(publisher search, opens in a new tab)Cochrane · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Zolpidem?
Plain-text summary, safe to quote verbatim:
Zolpidem is a prescription medication primarily used for the short-term treatment of insomnia. It belongs to a class of drugs known as sedative-hypnotics. It is typically taken in the evening. The reported plasma half-life is about 2.5 hours, which shapes dosing frequency.
Source: DoseRoutine — https://doseroutine.com/library/zolpidem
Zolpidem cheat sheet
DoseRoutine cheat sheet · Medication
Zolpidem
Zolpidem is a prescription medication primarily used for the short-term treatment of insomnia. It belongs to a class of drugs known as sedative-hypnotics.
Evidence
Strong
2 human randomized trials and regulatory approval on file.
Studied range
Meta-analysis-pooled trials and the lemborexant comparison used standard immediate-release and extended-release zolpidem doses studied for insomnia disorder, most commonly 5-10 mg (immediate release) or 6.25-12.5 mg (extended release) at bedtime
Route
Oral tablet, taken immediately before bedtime
Frequency studied
Once nightly, as needed for sleep onset or maintenance difficulty
Half-life
~2.5 h
Timing
in the evening
Storage
Room temperature, in original packaging, away from children
Schedule IV (US)Prescription only (US)FDA-approved under brand names including Ambien, Ambien CR, Edluar, and Zolpimist for short-term treatment of insomniaFDA has issued boxed-warning-level safety communications about complex sleep behaviors, including sleepwalking and sleep-driving, associated with zolpidem
Key references
- Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial (2019)
- Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis (2022)
- Efficacy and safety of Zolpidem in the treatment of insomnia disorder for one month: a meta-analysis of a randomized controlled trial (2021)
Studied ranges, not dosing advice. Not medical advice — talk to a clinician. doseroutine.com/library/zolpidem
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Zolpidem — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/zolpidem
What compounds are similar to Zolpidem?
Others in the medication category or studied for the same goals.